Diminishing returns, quantified
The ceiling in this class is anatomical: the same receptor populations that suppress appetite provoke nausea, and they saturate together.
Semaglutide
Page 4 of 18 of this archive, newest first.
What changing your injection day does to retatrutide exposure, and what it does not
What the pharmacokinetic data supports about dose timing, missed doses and interruption.
The ceiling is a tolerability finding, not an efficacy one
We looked at what the dose-ranging data supports about going higher, and it is thinner and less flattering than the market assumes.
Reading the retatrutide composition data without the press release
The trials measured mass. Nobody measured whether the participants got weaker.
Holding a dose is a decision, not a failure
A dose held long enough stops being a pause and becomes a maintenance decision. That transition is rarely made explicitly.
The ceiling is a tolerability finding, not an efficacy one
Where the curve flattens, what flattens with it, and what does not.
A reference interval is not a target, and a result outside one is not a diagnosis
A twelve-analyte panel in a perfectly healthy person has roughly even odds of producing at least one flagged result.
A reference interval is not a target, and a result outside one is not a diagnosis
The arithmetic of the reference change value, worked for the analytes that matter here.
The trade has decided the ceiling is arbitrary. The trials disagree.
Where the curve flattens, what flattens with it, and what does not.
A reference interval is not a target, and a result outside one is not a diagnosis
Almost every misreading of a laboratory panel is a misunderstanding of what a reference interval is and how much a result has to move before the movement means anything.
The escalation table is the thinnest page in the label
The published ladder exists because a protocol needed a single number. Practice has never followed it exactly, and the regulatory file never assumed it would.
The one randomised trial that combined an incretin with supervised exercise
The older-adult diet-and-exercise trials are the closest analogue to rapid pharmacological weight loss, and they are twenty years old.
Measuring more frequently generates more flags and not more information
The argument for a baseline panel is that it makes every subsequent result interpretable. The argument against frequent monitoring is that noise accumulates faster than…
Side effects, cost, supply, target: four reasons with four trajectories
A supply interruption is a discontinuation with no notice, no taper and no plan. That is a distinct clinical situation.
The supply gap as a clinical event
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
What the liraglutide schedule assumes about a person it has never met
The four-week step exists because four to five weeks is approximately how long a once-weekly drug takes to stop rising at a fixed dose. That is a good reason, and it is not…
The upper rungs, ranked by evidence
We looked at what the dose-ranging data supports about going higher, and it is thinner and less flattering than the market assumes.
The out-of-range flag is a statistical convention with a printer attached
The arithmetic of the reference change value, worked for the analytes that matter here.
The skeleton responds to load, and load is falling
Density is a proxy for strength and an imperfect one, particularly when soft-tissue thickness over the measurement site is changing.
Fructosamine, glycated albumin, and the shorter window nobody orders
The alternatives with shorter windows, what they measure, and why they are rarely ordered.